David M. McKean, PhD
Daniel Elgort, PhD
Oliver A. Hampton, PhD, MS
Phaedra Agius, PhD


Consensus molecular subtyping (CMS) of colorectal cancer (CRC) samples has increased understanding of the established subtypes on both a phenotypic and genotypic level and has enabled predicted outcomes for more personalized treatments. As a validation of both the quality, breadth and depth of Aster Insights’ real world clinical and molecular data, CMS groups were predicted for CRC tumor samples and then evaluated and compared with known features of the CRC consensus molecular subtypes.

View the full White Paper